RxDoctor Payments DataLook up a doctor →

Patrick Travis, MD

Hematology & Oncology · Fayetteville, ARNPI 1104897099

Payments from drug & device makers

$748,757in general payments, 2019–2025

Across 581 payments — averaging $1288.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$335K
  • TG Therapeutics, Inc.$177K
  • AbbVie$116K
  • Genentech, Inc.$70K
  • Novartis$20K
  • Bayer$5K
  • plus $26K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.47$334,807
TG Therapeutics, Inc.69$176,536
AbbVie26$116,111
Genentech, Inc.11$70,189
Novartis20$20,105
Bayer6$5,096
Karyopharm Therapeutics Inc.8$4,831
Rigel Pharmaceuticals, Inc.14$3,730
Sanofi24$3,608
E.r. Squibb & Sons, L.L.C.7$3,575
Bristol Myers Squibb41$2,155
GSK5$1,894
Epizyme, Inc.4$1,391
Johnson & Johnson(2 entities)65$1,260
Merck29$400
Amgen24$282
AstraZeneca16$268
Astellas Pharma US Inc13$198
Gilead(2 entities)14$189
Eisai Inc.10$142
Janssen Scientific Affairs, LLC1$126
Regeneron Healthcare Solutions, Inc.7$120
Jazz Pharmaceuticals Inc.6$95
Genmab U.S., Inc.6$91
Genentech USA, Inc.7$89
Exelixis Inc.7$88
Blueprint Medicines Corporation6$79
Daiichi Sankyo Inc.5$77
Lilly USA, LLC4$70
EMD Serono, Inc.5$64
Sun Pharmaceutical Industries Inc.3$63
Ipsen Biopharmaceuticals, Inc4$58
Beone Medicines USA, Inc.3$53
ADC Therapeutics America, Inc.3$52
Incyte Corporation4$50
Agios Pharmaceuticals, Inc.3$50
Iovance Biotherapeutics, Inc.3$46
Dendreon Pharmaceuticals LLC3$45
Boehringer Ingelheim2$40
Acceleron Pharma, Inc.3$38
Pharmacyclics LLC, An Abbvie Company2$37
Verastem, Inc.3$37
Helsinn Therapeutics (U.S.), Inc.2$33
AVEO Pharmaceuticals, Inc.2$32
Tersera Therapeutics LLC2$30
Pfizer2$28
Springworks Therapeutics, Inc.2$27
Blue Earth Diagnostics2$26
Servier Pharmaceuticals LLC2$26
Foundation Medicine, Inc.2$26
Morphosys, US Inc.2$24
Puma Biotechnology, Inc.1$24
Kyowa Kirin, Inc.2$22
Clovis Oncology, Inc.2$19
Sanofi-aventis U.S. LLC1$18
Acrotech Biopharma Inc.1$17
Lexicon Pharmaceuticals, Inc.1$16
Telix Pharmaceuticals1$15
Myovant Sciences Inc.1$15
Pharmacosmos Therapeutics Inc.1$14

How this compares

$748,757 in reported general payments places this provider in the 90th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$6,782,591
Medicare patients
1,428
Services billed
300,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fayetteville

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →